Palisade Bio (PALI) AI Stock Analysis

• Market Cap: $316.84M
• Dividend Yield: N/A
• Average Volume (3M): 4.53M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.16
• Revenue Growth: N/A
• EPS Growth: 71.95%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 149,003,200
• 10 Day Avg. Volume: 4,196,076
• 30 Day Avg. Volume: 4,525,639
• PEG Ratio: 0.08
• Price to Book (P/B): 1.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.06
• Enterprise Value/Market Cap: 0.48
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -151.21K
• Enterprise Value/Ebitda: -8.37
• 1Y Price Target: $11.40
• Price Target Upside: 496.86% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $2.00 ▲(4.71% Upside)
• Action: Reiterated Date: 03/21/26
• Date: Action: Reiterated 03/21/26

The score is primarily constrained by weak financial performance (minimal revenue, recurring losses, and ongoing cash burn), partially offset by low leverage and a materially strengthened 2025 balance sheet. Technicals are moderately supportive with price above key moving averages and neutral-to-positive momentum, while valuation is limited by negative earnings and no dividend data.

Positive Factors

Low leverage; stronger 2025 balance sheet

A materially strengthened 2025 balance sheet and negligible debt reduce near-term solvency risk and extend operational runway. This durable improvement gives management flexibility to fund clinical development and partnerships, lowering the probability of immediate financing distress over the next several quarters.

Positive Phase 1b translational data

Translational Phase 1b data showing rapid clinical, histologic and biomarker improvements and localized colonic activity meaningfully de-risks the lead asset's mechanism. Durable biological signals increase the probability of success in later trials and support targeted oral positioning in inflammatory GI indications.

Clinical advisory additions & Phase 2 plans

Adding experienced clinical advisors and planning a Phase 2 IND signals disciplined development governance and a clear clinical path. Strengthened clinical leadership and an explicit timeline reduce execution risk and improve trial design and regulatory interactions over the medium term.

Negative Factors

Persistent cash burn

Consistent multi-year negative operating and free cash flow is a durable constraint on strategy: it forces ongoing capital raises or partnerships, limits discretionary investment, and creates pressure on timelines. Continued burn reduces optionality and raises dilution or financing risk over the next 2–6 months and beyond.

Pre-revenue with recurring losses

The company remains essentially pre-revenue with persistent operating losses. Without demonstrated product revenue, sustainable cash generation depends on clinical success and licensing/commercial execution, making financial stability contingent on future milestone outcomes rather than current operations.

Ongoing reliance on external financing

A sizable 2025 capital infusion improved capitalization but did not restore profitability. Given continued losses and cash burn, the company is likely to need additional external funding to advance trials. Recurrent financing needs raise dilution risk and can constrain long-term strategic choices.

Palisade Bio Business Overview & Revenue Model

Company Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

How the Company Makes Money

null

Palisade Bio Financial Statement Overview

Summary

Financial results reflect an R&D-stage profile: near-zero revenue in most years and persistent operating/net losses, with negative operating cash flow and free cash flow every year. Positives include very low debt and a much stronger 2025 balance sheet, but the core risk remains continued cash burn and reliance on external financing until revenues scale.

Income Statement

The company remains pre-revenue/near-zero revenue across most years (2023 is the exception at ~$0.25M), with persistent operating losses. Losses improved from 2021 (EBIT about -$41.9M) to 2022–2024 (roughly -$15M range), but widened again in 2025 (EBIT about -$18.1M; net loss about -$16.8M). Overall, profitability is weak and the path to sustainable revenue is not yet evident in the reported results.

Balance Sheet

Leverage is very low (total debt near zero to <$0.5M historically, and reported as $0 in 2025), which reduces financial risk. However, equity and assets show a step-change higher in 2025 (equity ~$129.4M; assets ~$134.3M) versus 2024 (equity ~$7.5M; assets ~$10.9M), indicating a major capital raise and/or balance sheet event. Despite the stronger capitalization, returns remain negative due to ongoing losses.

Cash Flow

Cash burn is consistent, with operating cash flow and free cash flow negative every year shown (roughly -$10.8M to -$14.8M in 2021–2025). Cash burn improved versus 2024 in 2025 (operating/free cash flow about -$10.8M vs. -$12.2M), but the business is still not self-funding and will likely depend on external financing until revenues scale.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	250.00K	0.00	0.00
Gross Profit	-3.00K	0.00	250.00K	0.00	0.00
EBITDA	-18.06M	-14.42M	-12.28M	-14.24M	-24.22M
Net Income	-16.78M	-14.44M	-12.30M	-14.26M	-26.62M
Balance Sheet
Total Assets	134.34M	10.88M	14.05M	15.76M	12.51M
Cash, Cash Equivalents and Short-Term Investments	133.38M	9.82M	12.43M	12.38M	10.49M
Total Debt	71.00K	169.00K	369.00K	404.00K	199.00K
Total Liabilities	4.96M	3.39M	2.74M	3.28M	5.15M
Stockholders Equity	129.38M	7.49M	11.31M	12.48M	7.37M
Cash Flow
Free Cash Flow	-10.85M	-12.19M	-11.14M	-13.37M	-14.77M
Operating Cash Flow	-10.85M	-12.19M	-11.13M	-13.36M	-14.77M
Investing Cash Flow	0.00	0.00	-4.00K	-10.00K	-54.00K
Financing Cash Flow	134.44M	9.58M	11.19M	15.26M	24.61M

Palisade Bio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PALI, the sentiment is Positive. The current price of 1.91 is above the 20-day moving average (MA) of 1.86, above the 50-day MA of 1.78, and above the 200-day MA of 1.42, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 53.56 is Neutral, neither overbought nor oversold. The STOCH value of 49.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PALI.

Palisade Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRBP	57 Neutral	$149.52M	-1.38	-65.76%	―	―	-17.43%
ELDN	56 Neutral	$216.24M	―	-46.46%	―	―	72.35%
PALI	53 Neutral	$316.84M	-7.80	-228.64%	―	―	71.95%
OBIO	52 Neutral	$278.56M	-3,008.78	-170.45%	―	6.46%	-14.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PYXS	46 Neutral	$88.42M	-1.58	-87.28%	―	-82.53%	-52.00%